— Know what they know.
Not Investment Advice

HKPD NASDAQ

Cellyan Biotechnology Co., Ltd
1W: -2.1% 1M: -28.0% 3M: -76.4% YTD: -86.4% 1Y: -92.4%
$0.11
-0.00 (-2.06%)
 
Weekly Expected Move ±10.6%
$0 $0 $0 $0 $0
NASDAQ · Healthcare · Medical - Distribution · Tech Score Sell · Power 29 · $1.2M mcap · 3M float · 87.40% daily turnover · Short 31% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2M
52W Range0.096-1.72
Volume253,296
Avg Volume2,803,349
Beta2.23
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOChenyu Liang
Employees27
SectorHealthcare
IndustryMedical - Distribution
IPO Date2025-01-15
Website9zt.hk
Well Town Industrial Building
Hong Kong 999077
HK
852 2618-9289
About Cellyan Biotechnology Co., Ltd

Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.

Recent Insider Trades

NameTypeSharesPriceDate
CHAN Kam Leung 0 — 2026-03-18
Wong Lap Sun 0 — 2026-03-18
Wang Zifeng 0 — 2026-03-18
Liu Shu 0 — 2026-03-18
Zhou Mike Yao 0 — 2026-03-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms